Pharmacogenetics for safe codeine use in sickle cell disease

Pediatrics

Volumn 138, Issue 1, 2016, Pages

  Gammal, Roseann S ^a   Crews, Kristine R ^a   Haidar, Cyrine E ^a   Hoffman, James M ^a   Baker, Donald K ^a   Barker, Patricia J ^a   Estepp, Jeremie H ^a   Pei, Deqing ^a   Broeckel, Ulrich ^b   Wang, Winfred ^a   Weiss, Mitchell J ^a   Relling, Mary V ^a   Hankins, Jane ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CODEINE; CYTOCHROME P450 2D6; GENETIC MARKER; NARCOTIC ANALGESIC AGENT;

ARTICLE; CHILD; CLINICAL DECISION MAKING; CYP2D6 GENE; DRUG METABOLISM; DRUG SAFETY; GENETIC SCREENING; GENOTYPE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; PHARMACOGENETICS; PRESCRIPTION; PRIORITY JOURNAL; SICKLE CELL ANEMIA; ADENOIDECTOMY; ADOLESCENT; ANEMIA, SICKLE CELL; CLINICAL DECISION SUPPORT SYSTEM; CLINICAL PRACTICE; FEMALE; GENETIC MARKER; GENETICS; GENOTYPING TECHNIQUE; INFANT; MALE; METABOLISM; PAIN, POSTOPERATIVE; PHENOTYPE; PRESCHOOL CHILD; PROCEDURES; TENNESSEE; TONSILLECTOMY;

ADENOIDECTOMY; ADOLESCENT; ANALGESICS, OPIOID; ANEMIA, SICKLE CELL; CHILD; CHILD, PRESCHOOL; CLINICAL DECISION-MAKING; CODEINE; CYTOCHROME P-450 CYP2D6; DECISION SUPPORT SYSTEMS, CLINICAL; FEMALE; GENETIC MARKERS; GENOTYPE; GENOTYPING TECHNIQUES; HUMANS; INFANT; MALE; PAIN, POSTOPERATIVE; PHENOTYPE; PRACTICE PATTERNS, PHYSICIANS'; TENNESSEE; TONSILLECTOMY;

EID: 84976869634     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2015-3479     Document Type: Article

References (57)

1. US Food and Drug Administration. FDA Drug Safety Communication: Codeine use in certain children after tonsillectomy and/or adenoidectomy may lead to rare, but life-Threatening adverse events or death. 2012. Available at: Www.fda.gov/Drugs/DrugSafety/ucm313631.htm. Accessed June 15, 2015
2. US Food and Drug Administration. FDA Drug Safety Communication: Safety review update of codeine use in children; new boxed warning and contraindication on use after tonsillectomy and/or adenoidectomy. 2013. Available at: Www.fda.gov/Drugs/DrugSafety/ucm339112.htm. Accessed June 15, 2015
3. Woolf AD, Greco C. Why can't we retire codeine? Pediatrics. 2014;133(5). Available at: Www.pediatrics.org/cgi/content/full/133/5/e1354
4. Kaiser SV, Asteria-Penaloza R, Vittinghoff E, Rosenbluth G, Cabana MD, Bardach NS. National patterns of codeine prescriptions for children in the emergency department. Pediatrics. 2014;133(5). Available at: Www.pediatrics.org/cgi/content/full/133/5/e1139
5. Jerome J, Solodiuk JC, Sethna N, McHale J, Berde C. A single institution's effort to translate codeine knowledge into specific clinical practice. J Pain Symptom Manage. 2014;48(1): 119-126
6. Rieder MJ, Carleton B. Pharmacogenomics and adverse drug reactions in children. Front Genet. 2014;5: 78
7. Cartabuke RS, Tobias JD, Taghon T, Rice J. Current practices regarding codeine administration among pediatricians and pediatric subspecialists. Clin Pediatr (Phila). 2014;53(1): 26-30
8. Drug Enforcement Administration. Schedules of controlled substances: Rescheduling of hydrocodone combination products from Schedule III to Schedule II. Available at: Www.deadiversion. usdoj.gov/fed-regs/rules/2014/fr0822.htm. Accessed June 15, 2015
9. Crews KR, Gaedigk A, Dunnenberger HM, et al; Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin Pharmacol Ther. 2014;95(4): 376-382
10. Dunnenberger HM, Crews KR, Hoffman JM, et al. Preemptive clinical pharmacogenetics implementation: Current programs in five US medical centers. Annu Rev Pharmacol Toxicol. 2015;55: 89-106
11. Tremlett M, Anderson BJ, Wolf A. Procon debate: Is codeine a drug that still has a useful role in pediatric practice? Paediatr Anaesth. 2010;20(2): 183-194
12. Lazaryan M, Shasha-Zigelman C, Dagan Z, Berkovitch M. Codeine should not be prescribed for breastfeeding mothers or children under the age of 12. Acta Paediatr. 2015;104(6): 550-556
13. Fleming ML, Wanat MA. To prescribe codeine or not to prescribe codeine? J Pain Palliat Care Pharmacother. 2014;28(3): 251-254
14. Thorn CF, Klein TE, Altman RB. Codeine and morphine pathway. Pharmacogenet Genomics. 2009;19(7): 556-558
15. Eckhardt K, Li S, Ammon S, Schänzle G, Mikus G, Eichelbaum M. Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation. Pain. 1998;76(1-2): 27-33
16. Lötsch J, Rohrbacher M, Schmidt H, Doehring A, Brockmöller J, Geisslinger G. Can extremely low or high morphine formation from codeine be predicted prior to therapy initiation? Pain. 2009;144(1-2): 119-124
17. Kirchheiner J, Schmidt H, Tzvetkov M, et al. Pharmacokinetics of codeine and its metabolite morphine in ultrarapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J. 2007;7(4): 257-265
18. Gasche Y, Daali Y, Fathi M, et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med. 2004;351(27): 2827-2831
19. Caraco Y, Sheller J, Wood AJ. Pharmacogenetic determination of the effects of codeine and prediction of drug interactions. J Pharmacol Exp Ther. 1996;278(3): 1165-1174
20. Koren G, Cairns J, Chitayat D, Gaedigk A, Leeder SJ. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet. 2006;368(9536): 704
21. Genetic Testing Registry. CYP2D6 cytochrome P450, family 2, subfamily D, polypeptide 6. Available at: Www.ncbi. nlm. nih.gov/gtr/genes/1565. Accessed June 18, 2015
22. Ciszkowski C, Madadi P, Phillips MS, Lauwers AE, Koren G. Codeine, ultrarapid-metabolism genotype, and postoperative death. N Engl J Med. 2009;361(8): 827-828
23. Kelly LE, Rieder M, van den Anker J, et al. More codeine fatalities after tonsillectomy in North American children. Pediatrics. 2012;129(5). Available at: Www.pediatrics.org/cgi/content/full/129/5/e1343
24. Acetaminophen and codeine [package insert]. Available at: Https://dailymed. nlm. nih.gov.Accessed June 9, 2015
25. National Public Radio. Limits urged on the use of codeine to stop kids' coughs and pain. Available at: Www.npr.org/sections/health-shots/2015/12/10/459224775/limits-urged-on-The-use-ofcodeine-To-stop-kids-coughs-And-pain. Accessed December 12, 2015
26. Caudle KE, Klein TE, Hoffman JM, et al. Incorporation of pharmacogenomics into routine clinical practice: The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process. Curr Drug Metab. 2014;15(2): 209-217
27. Lerena A, Naranjo ME, Rodrigues-Soares F, Penas-Ledó EM, Fariñas H, Tarazona-Santos E. Interethnic variability of CYP2D6 alleles and of predicted and measured metabolic phenotypes across world populations. Expert Opin Drug Metab Toxicol. 2014;10(11): 1569-1583
28. Aklillu E, Persson I, Bertilsson L, Johansson I, Rodrigues F, Ingelman-Sundberg M. Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther. 1996;278(1): 441-446
29. McLellan RA, Oscarson M, Seidegård J, Evans DA, Ingelman-Sundberg M. Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians. Pharmacogenetics. 1997;7(3): 187-191
30. Green CR, Ndao-Brumblay SK, West B, Washington T. Differences in prescription opioid analgesic availability: Comparing minority and white pharmacies across Michigan. J Pain. 2005;6(10): 689-699
31. Gershman JA, Fass AD. Hydrocodone rescheduling amendment and pipeline products on the horizon. P&T. 2012;37(7): 399-404
32. Kuehn BM. FDA committee. FDA committee: More restrictions needed on hydrocodone combination products. JAMA. 2013;309(9): 862
33. Fox BI, Pedersen CA, Gumpper KF. ASHP national survey on informatics: Assessment of the adoption and use of pharmacy informatics in U.S. hospitals-2013. Am J Health Syst Pharm. 2015;72(8): 636-655
34. McCavit TL. Sickle cell disease. Pediatr Rev. 2012;33(5): 195-204, quiz 205-206
35. Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: Summary of the 2014 evidence-based report by expert panel members. JAMA. 2014;312(10): 1033-1048
36. Chang AK, Bijur PE, Lupow JB, Gallagher EJ. Comparative analgesic efficacy of oxycodone/acetaminophen vs. codeine/acetaminophen for short-Term pain management following ED discharge. Pain Med. 2015;16(12): 2397-2404
37. Chang AK, Bijur PE, Munjal KG, John Gallagher E. Randomized clinical trial of hydrocodone/acetaminophen versus codeine/acetaminophen in the treatment of acute extremity pain after emergency department discharge. Acad Emerg Med. 2014;21(3): 227-235
38. Hoffman JM, Haidar CE, Wilkinson MR, et al. PG4KDS: A model for the clinical implementation of pre-emptive pharmacogenetics. Am J Med Genet C Semin Med Genet. 2014;166C(1): 45-55
39. Fernandez CA, Smith C, Yang W, et al. Concordance of DMET plus genotyping results with those of orthogonal genotyping methods. Clin Pharmacol Ther. 2012;92(3): 360-365
40. Hicks JK, Crews KR, Hoffman JM, et al. A clinician-driven automated system for integration of pharmacogenetic interpretations into an electronic medical record. Clin Pharmacol Ther. 2012;92(5): 563-566
41. Bell GC, Crews KR, Wilkinson MR, et al. Development and use of active clinical decision support for preemptive pharmacogenomics. J Am Med Inform Assoc. 2014;21(e1): E93-e99
42. Crews KR, Cross SJ, McCormick JN, et al. Development and implementation of a pharmacist-managed clinical pharmacogenetics service. Am J Health Syst Pharm. 2011;68(2): 143-150
43. Black JL III, Walker DL, O'Kane DJ, Harmandayan M. Frequency of undetected CYP2D6 hybrid genes in clinical samples: Impact on phenotype prediction. Drug Metab Dispos. 2012;40(1): 111-119
44. Orliaguet G, Hamza J, Couloigner V, et al. A case of respiratory depression in a child with ultrarapid CYP2D6 metabolism after tramadol. Pediatrics. 2015;135(3). Available at: Www.pediatrics.org/cgi/content/full/135/3/e753
45. Joly P, Gagnieu MC, Bardel C, Francina A, Pondarre C, Martin C. Genotypic screening of the main opiate-related polymorphisms in a cohort of 139 sickle cell disease patients. Am J Hematol. 2012;87(5): 534-536
46. Yee MM, Josephson C, Hill CE, et al. Cytochrome P450 2D6 polymorphisms and predicted opioid metabolism in African American children with sickle cell disease. J Pediatr Hematol Oncol. 2013;35(7): E301-e305
47. Relling MV, Cherrie J, Schell MJ, Petros WP, Meyer WH, Evans WE. Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjects. Clin Pharmacol Ther. 1991;50(3): 308-313
48. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS. The CYP2D6 activity score: Translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther. 2008;83(2): 234-242
49. Rasmussen-Torvik LJ, Stallings SC, Gordon AS, et al. Design and anticipated outcomes of the eMERGEPGx project: A multicenter pilot for preemptive pharmacogenomics in electronic health record systems. Clin Pharmacol Ther. 2014;96(4): 482-489
50. American Academy of Pediatrics Committee on Bioethics and Committee on Genetics; and the American College of Medical Genetics and Genomics Social, Ethical, and Legal Issues Committee. Ethical and policy issues in genetic testing and screening of children. Pediatrics. 2013;131(3): 620-622
51. Elander J, Lusher J, Bevan D, Telfer P, Burton B. Understanding the causes of problematic pain management in sickle cell disease: Evidence that pseudoaddiction plays a more important role than genuine analgesic dependence. J Pain Symptom Manage. 2004;27(2): 156-169
52. Brown SE, Weisberg DF, Balf-Soran G, Sledge WH. Sickle cell disease patients with and without extremely high hospital use: Pain, opioids, and coping. J Pain Symptom Manage. 2015;49(3): 539-547
53. Brousseau DC, McCarver DG, Drendel AL, Divakaran K, Panepinto JA. The effect of CYP2D6 polymorphisms on the response to pain treatment for pediatric sickle cell pain crisis. J Pediatr. 2007;150(6): 623-626
54. Sequencing Costs DNA. National Human Genome Research Institute. Available at: Www.genome.gov/sequencingcosts/. Accessed June 15, 2015
55. Hicks JK, Swen JJ, Gaedigk A. Challenges in CYP2D6 phenotype assignment from genotype data: A critical assessment and call for standardization. Curr Drug Metab. 2014;15(2): 218-232
56. CPIC Informatics Working Group. PharmGKB. Available at: Https://www.pharmgkb.org/page/cpicInformatics. Accessed November 29, 2015
57. Twist GP, Gaedigk A, Miller NA, et al. Constellation: A tool for rapid, automated phenotype assignment of a highly polymorphic pharmacogene, CYP2D6, from whole-genome sequences. NPJ Genomic Med. 2016;1: 15007